secwatch.observer — SEC 8-K summary
======================================

Issuer:     InMed Pharmaceuticals Inc. (INM)
CIK:        0001728328
Form:       8-K
Filed at:   2024-09-20T23:59:59+00:00
Accession:  0001213900-24-080662
Event type: regulatory
Sentiment:  negative
Materiality: 0.75
Item codes: 3.01, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

InMed receives Nasdaq delisting notice for bid price non-compliance; hearing set for Oct 31, 2024
--------------------------------------------------------------------------------

- Nasdaq Staff issued delisting notice on Sept 17, 2024, after company failed to meet minimum $1.00 bid price by Sept 16, 2024 compliance deadline.
- Company timely filed an appeal; hearing before Nasdaq Listing Qualifications Panel scheduled for October 31, 2024.
- Appeal stays delisting pending panel decision; panel may grant up to 180 additional calendar days to regain compliance.
- No guarantee extension will be granted or that outcome will be favorable; shares risk suspension or delisting.
- Previously received 180-day extension on March 19, 2024 to cure deficiency.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1728328/000121390024080662/0001213900-24-080662-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1728328/000121390024080662/ea0215298-8k_inmed.htm
  HTML page:      https://secwatch.observer/filing/0001213900-24-080662

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer